Zai Lab Limited (ZLAB)

The company now

Zai Lab agreed on 22 October 2026 to place 11,340,000 American depositary shares (ADSs, the form in which its ordinary shares trade in the United States) with investors, for gross proceeds of about $250 million 23. The company said the money mainly supports the global development of zocilurtatug pelitecan (zoci), its antibody-drug conjugate aimed at a protein called DLL3 3. TCGX led the round 3.

The same week, on 23 October, the company shared the first global data for zoci with atezolizumab as first treatment for extensive-stage small cell lung cancer 4. Among 33 patients on the 1.6 mg/kg dose, the confirmed response rate was 81.8 percent 4. The company said a global Phase 3 study of that approach is expected to start by the end of 2026 4.

The latest quarterly results on file, for the second quarter of 2026, show total revenue of $106.3 million against $110.0 million a year earlier 1. Net loss was $50.8 million 1.

Cash, short-term investments and current restricted cash totaled $717.5 million at 30 June 2026 1. Zai Lab set 5 November 2026 for its third quarter results 13.

As of Nov 4, 2026. Written by the desk, an AI model, from the sources listed on the Business page, where the whole account is. Nothing here is advice.

Newer filings are on file since this was written; an update is queued.